Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of BCL6 and MUM1 Expression in Patients with Diffuse Large B cell Lymphoma and their Correlations with Staging and Prognosis in Iran

  • Rahimi, Hossein (Hematology Oncology Department, Mashhad University of Medical Science) ;
  • Jafarian, Amirhossein (Pathology Department, Cancer and Molecular Pathology Research Center, Mashhad University of Medical Science) ;
  • Samadi, Alireza (Internal Medicine Research Center for Patient Safety, Mashhad University of Medical Science) ;
  • Meamar, Bahram (Pathology, Cancer Research Center, Mashhad University of Medical Science) ;
  • Rahmani, Shaghayegh (Research Center for Patient Safety, Mashhad University of Medical Science)
  • Published : 2015.02.04
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkins lymphoma (NHL), accounting for approximately 25% of NHL cases. The aim of this study was to evaluate the association between the BCL6 and MUM1 gene expression and patient prognosis and stage. Materials and Methods: After ethical approval, in a cross-sectional study, tissue samples of 80 patients with diffuse large B-cell lymphoma were analyzed for BCL6 and MUM1 gene expression. Immunohistochemical staining was performed with division into categories of 0-5%, 5-25%, 26-50%, 51-75% and more than 75%. Other clinical and histological information such as lymph node involvement, T-stage, B symptoms and patient outcome were also recorded. Data were analyzed with SPSS version 16 and a P-value less than 0.05 was considered significant. Results: The patient mean age was $46.9{\pm}10.5$ years ($47.6{\pm}10.7$ and $46.1{\pm}9.6$ for males and females, respectively). A significant association was seen between lymphoma stage and BCL6 (p=0.045) but not MUM1 expression (p=0.09). However, the latter was associated with mortality (p=0.006) as was also the BCL6 level (p=0.006). Conclusions: : Overexpression of MUM1 and BCL6 is associated with poor prognosis in patients with diffuse large B-cell lymphoma.

Keywords

References

  1. Anderson J, Fordham S, Overman L, et al (2009). Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centrelike tumours displaying different survival characteristics. Int J Oncol, 35, 961-71.
  2. Bodoon K, Matalka I, Hayajneh R, Haddad Y, Gharaibeh W (2012). Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis. Asian Pac J Cancer Prev, 13, 3037-46. https://doi.org/10.7314/APJCP.2012.13.7.3037
  3. Colomo L, Lopez-Guillermo A, Perales M, et al (2003). Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood, 101, 78-84 https://doi.org/10.1182/blood-2002-04-1286
  4. Cook NR (2007). Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation, 115, 928-35. https://doi.org/10.1161/CIRCULATIONAHA.106.672402
  5. Davies AJ, Rosenwald A, Wright G, et al (2007). Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol, 136, 286-93. https://doi.org/10.1111/j.1365-2141.2006.06439.x
  6. De Mello CA, De Andrade VP, De Lima VC, Carvalho AL, Soares FA (2011). Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma. Leuk Lymphoma, 52, 1495-503. https://doi.org/10.3109/10428194.2011.573032
  7. Gascoyne RD (2014). The biology of diffuse large B cell lymphoma (dlbcl). Pathology, 1, 32.
  8. Gatter KC, Warnke RA (2001). Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. WHO classification of tumors. pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; p. 171-4.
  9. Habara T, Sato Y, Takata K, et al (2012). Germinal center B-celllike versus non-germinal center B-cell-like as important prognostic factor for localized nodal DLBCL. J Clin Exp Hematop, 52, 91-9. https://doi.org/10.3960/jslrt.52.91
  10. Kolokotronis A, Konstantinou N, Christakis I, et al (2005). Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: a clinical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 99, 303-10. https://doi.org/10.1016/j.tripleo.2004.03.028
  11. Muller AM, Ihorst G, Mertelsmann R, Engelhardt M (2005). Epidemiology of non-Hodgkin's lymphoma (NHL): Trends, geographic distribution, and etiology. Ann Hematol, 84, 1-12
  12. Sehn LH, Donaldson J, Chhanabhai M (2005). Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 23, 5027-33. https://doi.org/10.1200/JCO.2005.09.137
  13. Vaque JP, Martinez N, Batlle-Lopez A (2014). B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica, 99, 222-31. https://doi.org/10.3324/haematol.2013.096248
  14. Zhang Z, Shen Y, Shen D, Ni X (2012). Immunophenotype classification and therapeutic outcomes of Chinese primary gastrointestinal diffuse large B-cell lymphoma. BMC Gastroenterol, 25, 77.